Clinical Trial Update: Impact of Oral Ibandronate 150 mg Monthly on Structural Properties of Bone in Postmenopausal Osteoporosis (SPIMOS-3D) [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating the effect of monthly 150 mg oral ibandronate on bone structural properties in postmenopausal osteoporosis; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postmenopausal Osteoporosis

Drugs mentioned

• Boniva (ibandronate)

Snippet

Sponsor: Charite University, Berlin, Germany | Conditions: Osteoporosis, Postmenopausal | Phase 4 | Status: COMPLETED